A phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic lateral sclerosis

Overview of attention for article published in Frontiers in Neurology, June 2024

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

So far, Altmetric has seen 1 news story.

A promising clinical signal of a novel biologic combination immunotherapy in Amyotrophic Lateral Sclerosis (ALS) has been…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.